Every 424B that Healthcare Triangle Inc (HCTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HCTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCTI filings page.
Healthcare Triangle, Inc. is registering 28,000,000 shares of common stock for resale by Hudson Global Ventures, LLC under an equity purchase (ELOC) arrangement. This includes up to 27,950,000 ELOC Shares plus 50,000 shares issuable on exercise of a warrant at $0.00001 per share.
The company is not selling shares in this resale and will not receive proceeds from Hudson’s sales, but may raise up to $50,000,000 by directing Hudson to buy shares over about 36 months at a discount to market. Common stock outstanding would be 30,027,783 shares if all ELOC Shares and warrant shares are issued.
Healthcare Triangle highlights dilution and overhang risks from the ELOC and notes broad discretion over any ELOC proceeds, intended for general corporate purposes including operating needs, R&D and acquisitions. Recent moves include a $50.0 million Teyamé/Datono acquisition, a 1-for-60 reverse split and a $4.235 million convertible note financing.
Healthcare Triangle, Inc. amends its at-the-market program to increase the amount available for sale to $39,000,000 of common stock under the Sales Agreement with Spartan Capital Securities, LLC. This supplement notes $6,522,300.16 of shares were previously sold under the ATM Agreement and that sales may be made on Nasdaq or otherwise in at-the-market transactions.
The Sales Agent will sell on a commercially reasonable efforts basis and is not required to sell any specific number or dollar amount. The last reported sale price on Nasdaq on March 30, 2026 was $2.71 per share.
Healthcare Triangle, Inc. is offering 421,553 shares of common stock at a public offering price of $5.81 per share and is also offering up to 260,000 Pre-Funded Warrants to certain institutional investors to avoid post-closing ownership above 4.99% (or at purchaser election 9.99%).
The prospectus supplement shows 733,817 shares of Common Stock outstanding before this offering and, assuming full exercise of the Pre-Funded Warrants, 1,415,370 shares outstanding after this offering. Net proceeds are estimated at $3,682,635 before expenses. The offering is being placed by D. Boral Capital LLC and the securities are expected to be issued in a single closing.
Healthcare Triangle, Inc. (HCTI) has filed an S-3 prospectus covering the resale of 1,458,118 shares of common stock. These shares are issuable upon exercise of Inducement Warrants for 1,429,528 shares and Inducement Advisor Warrants for 28,590 shares that were issued in connection with an October 2025 warrant inducement transaction.
The company is not selling any shares in this prospectus and will not receive proceeds from Selling Stockholders’ resales. It may receive cash only if holders exercise the common warrants, which have a current exercise price of $3.00 per share, and could produce up to approximately $4.37 million in gross proceeds if fully exercised for cash.
The filing also explains that the new Inducement Warrants become exercisable after stockholder approval for issuances above 19.99% of outstanding common stock and include beneficial ownership caps of 4.99% or 9.99% to limit any single holder’s post-exercise ownership.
Healthcare Triangle, Inc. is launching an at-the-market offering of up to $20,000,000 of its common stock through Spartan Capital Securities as sales agent. Shares may be sold from time to time on Nasdaq under the symbol HCTI, with Spartan earning a 3% commission on gross sales.
The company plans to use any net proceeds for general corporate purposes, including potential acquisitions and working capital. An illustrative scenario assumes selling 9,569,377 shares at $2.09 per share, which would raise $20 million and increase as-adjusted net tangible book value to $1.48 per share, while creating $0.61 per-share dilution for new investors.
Recent actions include a 1-for-249 reverse stock split that reduced outstanding shares to 5,831,816, a warrant inducement that generated approximately $2.85 million in gross proceeds, and a $5.7 million asset and equity acquisition from Niyama Healthcare to expand mental health and hospital information systems capabilities.